Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

STEP 4

Novo Nordisk · Phase 3 · Completed · Enrollment 902

NCT03548987

EudraCT 2017-003473-34

Y axis: Change in body weight from baseline, %

1050-5-1004812162024Semaglutide, week 20, -8.3%SemaglutidePlacebo, week 20, 6.5%Placebo

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Semaglutide: week 20 -8.3%
  • Placebo: week 20 6.5%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.